H.C. Wainwright analyst Raghuram Selvaraju downgraded Kezar Life Sciences to Neutral from Buy without a price target The company elected to announce the voluntary cessation of enrollment of new patients and dosing of ongoing patients in the Phase 2b PALIZADE trial of its lead candidate zetomipzomib, pending further evaluation, the analyst tells investors in a research note. The firm cites the current status of the PALIZADE program, and the uncertainty around the outlook for zetomipzomib, for the downgrade.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue